Shares of Orthofix International N.V. (NASDAQ:OFIX) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $52.75.

A number of brokerages have weighed in on OFIX. BidaskClub raised Orthofix International N.V. from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 target price (up from $50.00) on shares of Orthofix International N.V. in a research report on Thursday, August 10th. TheStreet raised Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Thursday, August 10th. Finally, BTIG Research started coverage on Orthofix International N.V. in a report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 price target on the stock.

Orthofix International N.V. (OFIX) opened at 48.06 on Wednesday. Orthofix International N.V. has a one year low of $32.51 and a one year high of $49.60. The company has a market capitalization of $873.25 million, a PE ratio of 112.55 and a beta of 0.25. The company has a 50 day moving average price of $46.23 and a 200-day moving average price of $41.75.

Orthofix International N.V. (NASDAQ:OFIX) last issued its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. The business had revenue of $108.90 million during the quarter, compared to analyst estimates of $102.94 million. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. Orthofix International N.V.’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.41 EPS. Analysts expect that Orthofix International N.V. will post $1.57 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/30/orthofix-international-n-v-ofix-given-consensus-rating-of-buy-by-brokerages.html.

In other news, insider Raymond Fujikawa sold 6,364 shares of Orthofix International N.V. stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $47.06, for a total value of $299,489.84. Following the transaction, the insider now directly owns 31,084 shares in the company, valued at approximately $1,462,813.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brad Mason sold 2,733 shares of Orthofix International N.V. stock in a transaction on Monday, August 21st. The shares were sold at an average price of $48.10, for a total value of $131,457.30. Following the completion of the transaction, the chief executive officer now owns 188,053 shares in the company, valued at $9,045,349.30. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in OFIX. Teachers Advisors LLC increased its position in shares of Orthofix International N.V. by 18.2% in the fourth quarter. Teachers Advisors LLC now owns 35,600 shares of the medical device company’s stock worth $1,288,000 after buying an additional 5,489 shares in the last quarter. Capstone Asset Management Co. bought a new position in shares of Orthofix International N.V. during the first quarter worth about $204,000. Louisiana State Employees Retirement System bought a new position in shares of Orthofix International N.V. during the first quarter worth about $278,000. Nationwide Fund Advisors increased its position in shares of Orthofix International N.V. by 94.7% in the first quarter. Nationwide Fund Advisors now owns 24,441 shares of the medical device company’s stock worth $932,000 after buying an additional 11,888 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its position in shares of Orthofix International N.V. by 210.8% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 8,059 shares of the medical device company’s stock worth $307,000 after buying an additional 5,466 shares in the last quarter. Institutional investors and hedge funds own 94.43% of the company’s stock.

About Orthofix International N.V.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Analyst Recommendations for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.